Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix in Chinese patients with prostate cancer (PandaExtension)
NCT02015871Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of degarelix in prostate cancer (PCa), sponsored by Ferring Pharmaceuticals. Started Jan 2014; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02015871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015871.